Decibel Therapeutics, Inc. Common Stock
DBTX
DBTX was delisted on the 22nd of September, 2023.
38 hedge funds and large institutions have $46.7M invested in Decibel Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 4 closing their positions.
29% more capital invested
Capital invested by funds: $36.2M → $46.7M (+$10.5M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
3% less funds holding
Funds holding: 39 → 38 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$145K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$51.9K |
| 3 |
Baird Financial Group
Milwaukee,
Wisconsin
|
+$51.5K |
| 4 |
Bank of New York Mellon
New York
|
+$44.1K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$24.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$3.66M |
| 2 |
Millennium Management
New York
|
-$838K |
| 3 |
Barclays
London,
United Kingdom
|
-$787K |
| 4 |
NM
Newtyn Management
New York
|
-$55.9K |
| 5 |
E
Ergoteles
New York
|
-$48.1K |
DBTX Hedge Fund Activity: Q1 2023 in Review
38 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Decibel Therapeutics, Inc. Common Stock (DBTX) for Q1 2023, worth a combined $46.7M — up 29% from $36.2M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of DBTX and 3 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 11 added.
The largest buyer was Point72 Asset Management, adding an estimated $145K. The largest seller was Citadel Advisors, exiting entirely with an estimated $3.66M sold.
- 38 institutional investors held Decibel Therapeutics, Inc. Common Stock (DBTX) as of Q1 2023, down from 39 in Q4 2022.
- Funds reported $46.7M of Decibel Therapeutics, Inc. Common Stock stock for Q1 2023, up 29% quarter-over-quarter.
- 3 funds opened new Decibel Therapeutics, Inc. Common Stock positions in Q1 2023 and 4 closed out, a net change of -1 holder.
- The largest Decibel Therapeutics, Inc. Common Stock buyer in Q1 2023 was Point72 Asset Management, an estimated $145K added.
- The largest Decibel Therapeutics, Inc. Common Stock seller in Q1 2023 was Citadel Advisors, an estimated $3.66M sold.
Based on aggregated 13F filings for Q1 2023.